Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Poor trading liquidity
Profitability factor
Greatly undervalued vs peers
Very low or no dividends
Very poor margins and returns
Risk / Profitability
Risk: High
Profitability: Favourable
Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Poor trading liquidity
Profitability factor
Greatly undervalued vs peers
Very low or no dividends
Very poor margins and returns
£ 3.55
About
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate...
About
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with...
